UbiVac’s therapies and technologies are being tested in preclinical and clinical (human) trials. Each of the company’s vaccines, supporting platforms and vectors are evaluated, first for proof of concept, then for safety and finally for effectiveness in humans.
Preclinical proof of concept studies are completed in UbiVac’s labs. Phase II and III clinical trials are conducted under physician supervision and FDA sanction among living patients who are suffering from each particular disease under investigation.
The Pipeline table in this section specifically details the progress of each of the company’s technologies.